Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03926013 · ClinicalTrials.gov registry record · Phase 1
A Study of JNJ-63898081 in Participants With Advanced Stage Solid Tumors
A Phase 1 study of Neoplasms, sponsored by Janssen Research & Development.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
- 7
- Study locations
NCT03926013 is a Phase 1 study of Neoplasms that has completed, run by Janssen Research & Development. The registered enrollment target is 40 participants, below the 1,621-participant average among 158 other Neoplasms trials with a reported enrollment target (98% lower). The trial reports 7 study locations across 7 states.
The verdict
NCT03926013, a Phase 1 study of Neoplasms, has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
- 7
- Study locations
Study Summary
The main purpose of this study are to determine the recommended Phase 2 dose (RP2D) regimen and the maximum tolerated dose, and to determine the safety of JNJ-63898081.
Conditions Studied
Interventions
- DRUG JNJ-63898081
Study Locations (7)
California
- University of California, San Francisco - San Francisco
Maryland
- NIH Clinical Center - Bethesda
New York
- Columbia University Medical Center - New York
Utah
- University of Utah - Salt Lake City
Washington
- University of Washington - Seattle
British Columbia
- British Columbia Cancer Agency - Vancouver
Ontario
- Princess Margaret Hospital - Toronto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2019-05-01 |
| Est. Completion | 2021-09-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03926013
The ClinicalTrials.gov registry entry for NCT03926013 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,621-participant average among 158 other Neoplasms trials with a reported enrollment target (98% lower). The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Neoplasms appearing as the primary indexed condition, and to 1 intervention - of which JNJ-63898081 is the first listed.
NCT03926013 reports 7 study locations spanning 7 distinct geographic areas - top geographies include California, Maryland, New York.
Frequently Asked Questions
What is clinical trial NCT03926013 about?
NCT03926013 is a clinical study titled "A Study of JNJ-63898081 in Participants With Advanced Stage Solid Tumors". The main purpose of this study are to determine the recommended Phase 2 dose (RP2D) regimen and the maximum tolerated dose, and to determine the safety of JNJ-63898081.
What is the current status of trial NCT03926013?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2019-05-01. Estimated completion is 2021-09-02.
What conditions does trial NCT03926013 study?
This clinical trial studies the following conditions: Neoplasms.
What interventions are being tested in trial NCT03926013?
The interventions under investigation include: JNJ-63898081 (DRUG).
Who is sponsoring clinical trial NCT03926013?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03926013 being conducted?
This trial has 7 study locations across California, Maryland, New York, Utah, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Clinical Activity of RO7673396 in Participants With Advanced Solid Tumors Harboring Rat Sarcoma Viral Oncogene Homolog (RAS) Mutation(s)
RECRUITING · Phase 1
-
A Study of GSK5764227 in Participants With. Advanced Solid Tumors (EMBOLD PanTumor-101)
RECRUITING · Phase 1
-
Adoptive Cell Therapy Long-term Follow-up (LTFU) Study
RECRUITING · Phase 1
-
Two Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Solid Malignancies
RECRUITING · Phase 1
-
EMB-01 in Patients With Advanced/Metastatic Gastrointestinal Cancers
RECRUITING · Phase 1
-
Open-Label Study of Pocenbrodib Alone and in Combination With Abiraterone Acetate, Olaparib, or 177Lu-PSMA-617
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.